Journal of Molecular Genetics and Gene Research ISSN: 3070-071X

PRIME OPEN ACCESS

Volume 2, Issue 1

Research Article

Date of Submission: 07 May, 2026
Date of Acceptance: 02 Jun, 2026
Date of Publication: 11 Jun, 2026

Genomics and Oscc Cure

Dr. Amruta Sheth*

A J Institute of Medical and Dental Sciences, Mangalore, India
MFDS, Royal College of Surgeons, Edinburgh, UK

***Corresponding Author:** Dr. Amruta Sheth, A J Institute of Medical and Dental Sciences, Mangalore, India; MFDS, Royal College of Surgeons, Edinburgh, UK.

Citation: Sheth, A. (2026). Genomics and Oscc Cure. *J Mol Genet Gene Res, 2*(1), 01-06.

Highlights
Multi-omics reveals molecular complexity of OSCC beyond genomics alone
Integration of proteomics and metabolomics improves biomarker discovery
Enables precision oncology and rational drug combination strategies
Identifies mechanisms of therapeutic resistance

Abstract
Oral Squamous Cell Carcinoma (OSCC) is a highly heterogeneous malignancy characterized by complex molecular alterations that cannot be fully understood through single-omics approaches. Multi-omics integration, encompassing genomics, proteomics, and metabolomics, provides a comprehensive framework for understanding tumor biology and therapeutic vulnerabilities. Genomics identifies driver mutations, proteomics elucidates functional protein networks, and metabolomics captures metabolic reprogramming essential for tumor survival. Integrative analysis enables improved biomarker discovery, identification of novel drug targets, and prediction of therapeutic response. "This paper presents a theoretical analysis of literature-derived data to examine advances in multi-omics approaches in Oral Squamous Cell Carcinoma and their implications for Targeted therapy, Immunotherapy and drugs resistance."

Keywords: Oscc, Multi-Omics, Genomics, Proteomics, Metabolomics, Targeted Therapy, Precision Oncology

Introduction
Oral Squamous Cell Carcinoma (OSCC) accounts for the majority of oral malignancies and remains associated with poor prognosis due to late-stage diagnosis and therapy resistance. Traditional molecular studies have largely focused on genomic alterations; however, these do not fully capture the dynamic functional state of tumor cells.
Multi-omics integration enables:
Cross-validation of molecular findings
Functional interpretation of genomic alterations
Systems-level modeling of tumor progression

Multi-Omics Framework in OSCC
Description:
A layered schematic:
Layer 1: Genomics (DNA mutations, CNVs)
Layer 2: Proteomics (protein expression, signaling pathways)
Layer 3: Metabolomics (metabolic flux, metabolites)
Output: Biomarkers → Drug targets → Personalized therapy

Genomics Landscape of OSCC
Key Genetic Alterations
TP53 mutations (genomic instability)
PI3K/AKT pathway activation

NOTCH signaling alterations

Limitations of Genomics Alone

Poor correlation with protein activity
Inability to predict metabolic phenotype
Limited utility in therapy selection without integration

Proteomics: Functional Layer of Tumor Biology

Protein Expression and Signaling

Proteomics identifies dysregulated pathways:
EGFR signaling
MAPK cascade
PI3K/AKT/mTOR axis

Clinical Applications

Drug target validation
Predictive biomarkers
Therapy monitoring



Figure: 1 and 2





Figure 3

This figure illustrates the hierarchical integration of:
Genomics (DNA mutations, CNVs)
Proteomics (protein expression, signaling pathways)
Metabolomics (metabolic flux and metabolites)
These layers converge into: → Biomarker discovery
→ Drug target identification
→ Precision therapy
Dysregulated signaling pathways in OSCC
Chart Type: Pathway interaction network
Content: Nodes representing proteins (EGFR, AKT, mTOR) with edges showing activation/inhibition

Metabolomics: Tumor Phenotype and Adaptation

Metabolic Reprogramming

Aerobic glycolysis (Warburg effect)
Glutamine dependency
Lipid biosynthesis

Therapeutic Implications





Figure 4 and 5

Targeting metabolic enzymes
Monitoring treatment response via metabolite profiles Figure 4 (Chart)
Metabolic alterations in OSCC
Chart Type: Bar graph or heatmap



Figure 6

Content: Elevated lactate, glutamine, lipid metabolites vs normal tissue

Integration of Multi-Omics Data

Systems Biology Approach

Integration methods:
Network-based modeling
Machine learning algorithms
Pathway enrichment analysis

Clinical Benefits

Improved diagnostic accuracy
Identification of molecular subtypes
Personalized therapy design



Figure 7

Multi-omics-driven precision medicine pipeline
Flow: Patient sample → Multi-omics profiling → Data integration → Target identification → Drug selection

Implications for Cancer Drug Development

Targeted Therapy



Figure 8

Multi-Omics Identifies Actionable Targets:
EGFR inhibitors (e.g., cetuximab)
PI3K inhibitors
CDK inhibitors

Immunotherapy

PD-1/PD-L1 axis modulation
Tumor microenvironment profiling via proteomics

Metabolism-Based Therapies
Glycolysis inhibitors
Glutaminase inhibitors
Multi-omics-guided drug targeting strategy
Chart Type: Integrated pathway map showing drug intervention points

Drug Resistance Mechanisms Multi-omics reveals:
Genetic mutations driving resistance
Protein pathway reactivation
Metabolic adaptation
Clinical Impact
Predicting resistance early
Designing combination therapies

Challenges and Limitations
Data integration complexity
High computational requirements
Limited clinical translation
Cost constraints

Future Perspectives
AI-driven multi-omics integration
Single-cell omics technologies
Liquid biopsy applications
Real-time treatment monitoring

Conclusion
Multi-omics integration represents a transformative approach in understanding OSCC biology. By bridging genomic alterations with functional and metabolic phenotypes, it enables more accurate biomarker discovery and targeted therapeutic strategies. This systems-level approach is essential for advancing precision oncology and improving patient outcomes [1-10].

Declarations
Funding: None
Conflicts of Interest: The authors declare no conflict of interest
Ethical Approval: Not applicable

References
1. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582.
2. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–282.
3. Proteomics in cancer: A review of technologies and applications. Nat Methods. 2016;13:35–45.
4. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.
5. Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819–1875.
6. Licitra L, Mesia R, Rivera F, et al. Evaluation of cetuximab in head and neck cancer. J Clin Oncol. 2011;29(25):3340–3346.
7. Dienstmann R, Rodon J, Tabernero J. Biomarker-driven cancer therapy. Cancer Discov. 2013;3(4):364–379.
8. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83.
9. Zhang A, Sun H, Wang X. Recent advances in metabolomics in cancer. Mol Cancer. 2012;11:1–9.
10. Chen YP, Chan ATC, Le QT, et al. PD-1/PD-L1 inhibitors in head and neck cancer. Lancet Oncol. 2019;20(5):e240–e251.